Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Fudan University

Status: Enrolling

Conditions: Breast Cancer

Treatments: Drug: Sacituzumab Govitecan

Study type: Observational

Funder types: Other

Identifiers

NCT06356519

YOUNGBC-29

Details and patient eligibility

About

The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.

Enrollment: 150 estimated patients

Sex: Female

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients aged over 18 years old.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. Plan to receive or has received Sacituzumab Govitecan monotherapy
4. Available medical history.

Exclusion criteria

1. Incomplete medical history.
2. Pregnancy or breast-breeding

Trial design

150 participants in 1 patient group

Sacituzumab Govitecan

Description:

Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w

Treatment:

Drug: Sacituzumab Govitecan